Undesirable patient outcomes
During EGFR-TKI treatment, of the total 232 older advanced NSCLC
patients, 72 (31.0%) experienced >=grade 3
EGFR-TKI-related AEs, of which 30 (41.7%) patients experienced liver
function–related AEs (e.g., elevated transaminase), 23 (31.9%)
patients experienced skin-related AEs (e.g., rash, paronychia), and 12
(16.7%) patients experienced gastrointestinal AEs (e.g., diarrhea,
nausea, loss of appetite). In addition, 5 patients experienced
>=grade 3 pneumonitis, Of the total 232 patients, 86
(37.1%) had at least one unexpected hospitalization and 21 (17.2%)
patients had two or more hospitalizations. In addition,40 (17.2%)
patients were hospitalized because of exacerbation of NSCLC, 23 (9.9%)
because of EGFR-TKI-related AEs, and 37 (16.0%) because of
complications unrelated to NSCLC or EGFR-TKI-related AEs.
Undesirable outcomes in PP(+) and PP(–) older advanced NSCLC